This revealed high IP activity in the field of PCSKs, with patents ranging from biomarkers of diabetes (PCSK1 and PCSK2), to biomarkers and drug targets in cancer (FURIN and PCSK6), with the highest number of patents expectedly related to PCSK9 (Supplementary Table S6). This evidence concerns the gene PCSK1 and cancer.